Eisai plants molecular glue SEED with $1.5B biobucks deal in neuro, oncology

Big Pharmas remain stuck to the idea of molecular glue degraders. The latest company to see an opportunity is Japan’s Eisai, which has signed a $1.5 billion biobucks pact with SEED Therapeutics for undisclosed neurodegeneration and oncology targets.